Last reviewed · How we verify
IL-2 pre-treated CD19 cells
IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity.
IL-2 pre-treated CD19-targeted cells enhance immune recognition and elimination of CD19-expressing B-cell malignancies through cytokine-primed cellular immunity. Used for B-cell malignancies expressing CD19.
At a glance
| Generic name | IL-2 pre-treated CD19 cells |
|---|---|
| Sponsor | jiangjingting |
| Drug class | Adoptive cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is a cell therapy approach where CD19-expressing cells are pre-treated with interleukin-2 (IL-2) to enhance their immunogenicity and anti-tumor activity. The IL-2 pre-treatment activates and expands the cells, potentially improving their ability to target and kill CD19+ B-cell malignancies. This represents an adoptive cell therapy strategy combining cytokine priming with cellular immunotherapy.
Approved indications
- B-cell malignancies expressing CD19
Common side effects
- Cytokine release syndrome
- Immune activation-related toxicity
- Infusion reactions
Key clinical trials
- Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) (PHASE2)
- Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (PHASE1)
- A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) (PHASE1)
- Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-2 pre-treated CD19 cells CI brief — competitive landscape report
- IL-2 pre-treated CD19 cells updates RSS · CI watch RSS
- jiangjingting portfolio CI